Burrill & Co. and the Infinity Group are joining forces to pursue investments in Chinese life science companies.
San Francisco-based Burrill, a venture capital/private equity player, and Israel- and Chine-based Infinity will co-invest in U.S. dollars and Chinese renminbi as equal partners, according to a press release.
The deal calls for Burrill to establish headquarters for its China operations in Hong Kong, where Infinity already has operations. The JV will also take advantage of Infinity’s 10 offices in the People’s Republic and others in the U.S., Europe and Asia.
For Infinity it’s a chance to broaden its American footprint, aiming to introduce Israeli, U.S. and European technologies in China.
"We are very excited about this joint venture as this partnership will be able to build upon our complementary focus areas internationally," Burrill & Co. CEO Steven Burrill said in prepared remarks. "We will be able to bring our venture capital/private equity operations with our focus on innovation to delivery in healthcare, as well as activities in life sciences publications and events to Infinity’s extensive operations and networks in China."
